Cost-effectiveness analysis of implementing polygenic risk score in a workplace cardiovascular disease prevention program.

Autor:	Mujwara D; Allelica, Inc., New York, NY, United States., Kintzle J; Allelica, Inc., New York, NY, United States., Di Domenico P; Allelica, Inc., New York, NY, United States., Busby GB; Allelica, Inc., New York, NY, United States., Bottà G; Allelica, Inc., New York, NY, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in public health [Front Public Health] 2023 Jul 11; Vol. 11, pp. 1139496. Date of Electronic Publication: 2023 Jul 11 (Print Publication: 2023).
DOI:	10.3389/fpubh.2023.1139496
Abstrakt:	Background: Polygenic risk score for coronary artery disease (CAD-PRS) improves precision in assessing the risk of cardiovascular diseases and is cost-effective in preventing cardiovascular diseases in a health system and may be cost-effective in other settings and prevention programs such as workplace cardiovascular prevention programs. Workplaces provide a conducitve environment for cardiovascular prevention interventions, but the cost-effectiveness of CAD-PRS in a workplace setting remains unknown. This study examined the cost-effectiveness of integrating CAD-PRS in a workplace cardiovascular disease prevention program compared to the standard cardiovascular workplace program without CAD-PRS and no-workplace prevention program. Methods: We developed a cohort simulation model to project health benefits (quality-adjusted life years gained) and costs over a period of 5 years in a cohort of employees with a mean age of 50 years. The model health states reflected the risk of disease (coronary artery disease and ischemic stroke) and statin prevention therapy side effects (diabetes, hemorrhagic stroke, and myopathy). We considered medical and lost productivity costs. Data were obtained from the literature, and the analysis was performed from a self-insured employer perspective with future costs and quality-adjusted life years discounted at 3% annually. Uncertainty in model parameter inputs was assessed using deterministic and probabilistic sensitivity analyses. Three programs were compared: (1) a workplace cardiovascular program that integrated CAD-PRS with the pooled cohort equation-a standard of care for assessing the risk of cardiovascular diseases (CardioriskSCORE); (2) a workplace cardiovascular prevention program without CAD-PRS (Standard-WHP); and (3) no-workplace health program (No-WHP). The main outcomes were total costs (US $2019), incremental costs, incremental quality-adjusted life years, and incremental cost-effectiveness ratio. Results: CardioriskSCORE lowered employer costs ($53 and $575) and improved employee quality-adjusted life years (0.001 and 0.005) per employee screened compared to Standard-WHP and No-WHP, respectively. The effectiveness of statin prevention therapy, employees' baseline cardiovascular risk, the proportion of employees that enrolled in the program, and statin adherence had the largest effect size on the incremental net monetary benefit. However, despite the variation in parameter input values, base case results remained robust. Conclusion: Polygenic testing in a workplace cardiovascular prevention program improves employees' quality of life and simultaneously lowers health costs and productivity monetary loss for employers. Competing Interests: DM, JK, PD, GBB, and GB were employed by the Allelica, Inc. (Copyright © 2023 Mujwara, Kintzle, Di Domenico, Busby and Bottà.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu